Venous thromboembolism following initiation of atypical antipsychotics in two geriatric patients

Maestri, Thomas J.; Koenig, Jessica; Masuda, Christine; Smith, Tawny; Garcia-Pittman, Erica C.

doi:10.9740/mhc.2017.03.051

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19] An association between antipsychotic medication and venous thromboembolism is discussed since many years. [20] In our patient, however, the venous thromboembolism has started before initiation of antipsychotic therapy. Of note, in a case series of patients who developed a psychosis after COVID-19, three out of ten reported patients also suffered from venous thromboembolism.…”

Section: Discussionmentioning

confidence: 62%

Pulmonary embolism and acute psychosis, a case report of an outpatient with a mild course of COVID-19

Makivic

Stöllberger

Schauer

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction The increased risk for thromboembolism in hospitalized COVID-19 patients has been communicated extensively. The fact that home quarantined patients can develop pulmonary embolism, however, has so far not been reported. Furthermore, attention should be brought to psychotic developments in COVID-19 patients.Case Presentation We report a 46-year-old previously healthy patient with a mild course of COVID-19, who developed a massive pulmonary embolism with right heart strain while being home quarantined. He was hospitalized and anticoagulant therapy was started. Nine days after admission, the patient appeared increasingly psychotic and suffered from hallucinations as well as paranoid thoughts. After treatment with risperidone and valproate the patient’s condition improved. At a follow-up one month after discharge, he was completely recovered regarding the respiratory, cardiac and psychic situation.Conclusion SARS-CoV-2 infection cannot only increase the prevalence of thromboembolism in hospitalized patients, but also in outpatients. COVID-19 also increases the risk of developing psychiatric reactions.

show abstract

Section: Discussionmentioning

confidence: 62%

Pulmonary embolism and acute psychosis, a case report of an outpatient with a mild course of COVID-19

Makivic

Stöllberger

Schauer

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…More than 50 years ago, an association between venous thromboembolism and psychoses had been described [ 25 ]. An association between antipsychotic medication and venous thromboembolism is discussed since many years [ 26 ]. In our patient, however, the venous thromboembolism has started before initiation of antipsychotic therapy.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Embolism and Acute Psychosis, a Case Report of an Outpatient with a Mild Course of COVID-19

Makivic

Stöllberger

Schauer

et al. 2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The increased risk for thromboembolism in hospitalized COVID-19 patients has been communicated extensively. The fact that home quarantined patients can develop pulmonary embolism, however, has so far not been reported. Furthermore, attention should be brought to psychotic developments in COVID-19 patients. We report a 46-year-old previously healthy patient with a mild course of COVID-19, who developed a massive pulmonary embolism with right heart strain while being home quarantined. He was hospitalized and anticoagulant therapy was started. Nine days after admission, the patient appeared increasingly psychotic and suffered from hallucinations as well as paranoid thoughts. After treatment with risperidone and valproate, the patient’s condition improved. At a follow-up 1 month after discharge, he was completely recovered regarding the respiratory, cardiac, and psychic situation. SARS-CoV-2 infection can not only increase the prevalence of thromboembolism in hospitalized patients but also in outpatients. COVID-19 also increases the risk of developing psychiatric reactions.

show abstract

“…Whenever clinical symptoms of venous thromboembolism occur, the diagnosis should be confirmed or excluded immediately by imaging and laboratory tests. [12] Patients treated with olanzapine and risperidone should be monitored clinically for venous thromboembolism to ensure early detection and intervention, and possible discontinuation of treatment with olanzapine and risperidone should be considered if the diagnosis of venous thromboembolism is established. [13].…”

Section: Discussion:-mentioning

confidence: 99%

Venous Thromboembolism and Antipsychotics: A Case Report

Azeroual¹,

Laboudi²,

Ouanass³

2020

IJAR

View full text Add to dashboard Cite

Deep vein thrombosis is a multifactorial disease characterized by a multitude of risk factors favoring its occurrence. Among these factors, the iatrogenic and especially medicinal factors which remain the most easily avoidable, however quite difficult to prove and establish. [1] Patients with mental illness put on antipsychotics have a higher risk of developing venous thromboembolism compared to the general population. [2] VTE venous thromboembolism is a serious and life-threatening condition. Manifestations of VTE include deep vein thrombosis (DVT) and pulmonary embolism (PE). Considering the importance of this condition, considerable sums are spent on treatment in European and North American countries. VTE affects approximately 1.0 to 1.8 people per 1,000 per year [3]. The incidence increases exponentially with age and the risk increases considerably in

show abstract

Venous thromboembolism following initiation of atypical antipsychotics in two geriatric patients

Cited by 5 publications

References 19 publications

Pulmonary embolism and acute psychosis, a case report of an outpatient with a mild course of COVID-19

Pulmonary embolism and acute psychosis, a case report of an outpatient with a mild course of COVID-19

Pulmonary Embolism and Acute Psychosis, a Case Report of an Outpatient with a Mild Course of COVID-19

Venous Thromboembolism and Antipsychotics: A Case Report

Contact Info

Product

Resources

About